Sarepta Therapeutics Inc. (NASDAQ:SRPT) shares are up on Wednesday following the announcement of promising clinical results from its siRNA programs targeting neuromuscular diseases.

Promising Early Data From Sarepta Programs

Sarepta Therapeutics recently shared the first clinical results from its siRNA programs, specifically SRP-1001 and SRP-1003, which are designed to treat facioscapulohumeral muscular dystrophy (FSHD1) and myotonic dystrophy type 1 (DM1), respectively.

Early results from the Phase 1/2 trials showed dose-dependent muscle exposure and favorable tolerability, reinforcing confidence in the potential of these investigational treatments.

The company highlighted that both SRP-1001 and SRP-1003 demonstrated significant reductions in target proteins and mRNA after a single dose, with most adverse events reported as mild to moderate.

This progress is particularly important as the company aims to address the challenges of delivering RNA-targeted therapies effectively to patients suffering from these rare genetic diseases.

Last week, Sarepta Therapeutics said it plans to submit supplemental new drug applications to the U.S. Food and Drug Administration (FDA) for Duchenne muscular dystrophy treatments by the end of April, as detailed in the regulatory update.

Sarepta requested a meeting with the FDA to discuss submitting supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) to traditional approvals.

Sarepta Technical Indicators

Currently, the stock is trading 18.2% above its 20-day simple moving average (SMA) and 2% above its 100-day SMA, indicating short-term strength despite a longer-term downtrend.

Over the past 12 months, shares have decreased by 76.08%, and they are currently positioned closer to their 52-week lows than highs, reflecting ongoing challenges for the company.

The RSI is at 49.29, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, the MACD shows a value of -0.3789, with the signal line at -0.5709, indicating a bullish momentum as the MACD is above the signal line.

The combination of a neutral RSI and bullish MACD suggests mixed momentum, indicating that while there is potential for upward movement, caution is warranted given the stock’s recent performance.

  • Key Resistance: $23.00
  • Key Support: $16.50

Analyst Consensus & Recent Actions: The stock carries a Hold Rating with an average price target of $22.57. Recent analyst moves include:

  • Oppenheimer: Outperform (Maintains Target to $37.00) (Mar. 19)
  • Mizuho: Outperform (Raises Target to $31.00) (Mar. 13)
  • Citigroup: Sell (Raises Target to $9.00) (Mar. 10)

SRPT Price Action: Sarepta Therapeutics shares were up 28.11% at $22.56 at the time of publication on Wednesday, according to Benzinga Pro data.

Image via Shutterstock